Preventive nutrition brand Good Monk is on track to close the current financial year with Rs 150 crore in annual recurring revenue — a 10-fold increase in 15 months.
The growth is coming with quality: repeat-purchase revenue is growing faster than overall revenue, signalling genuine customer adoption rather than discount-driven trials. The company has also staged a sharp profitability turnaround, improving from a negative 50% EBITDA position and now targeting EBITDA positivity within this fiscal year.
Notably, more than 65% of revenue now comes from non-metro cities — a reminder that India's nutrition opportunity lies far beyond the metros. Its flagship products have become among the top-ranked multivitamins on Amazon India, and the brand is expanding into more specific, clinically validated nutrition products across age groups, supported by end-product clinical trials.
Good Monk says it will keep focusing on everyday nutrition deficiencies at price points suitable for Indian households — a positioning that has clearly found its market.
Why it matters for founders
Good Monk's 10x run paired with a march to EBITDA positivity is the rare combination of hypergrowth and discipline. For D2C founders: repeat revenue is the metric that matters, non-metros are where the volume lives, and clinical validation can be a genuine differentiator in crowded wellness categories.